Counselors in Lebanon, VA Accepting Medicare

11 Counselors found. Showing 1 - 11

Cindy Joann Davis, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 2050 Pioneer Dr, Lebanon, VA 24266 Phone: 276-202-2816

Kristie L Bubke, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 102 Kemp St, Lebanon, VA 24266 Phone: 276-889-3063    Fax: 276-889-5025

Michael D Bush, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 160 Rogers St, Lebanon, VA 24266 Phone: 276-889-3785    Fax: 276-889-2842

Stacy Nichole Davis, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 78 Rogers St, Lebanon, VA 24266 Phone: 276-889-3785

Amy Clear, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 160 Rogers St, Lebanon, VA 24266 Phone: 276-889-3785    Fax: 276-889-2842

Kelly Elizabeth Smith, LCSW, CSAC Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 216 Gilmer Street, Lebanon, VA 24266 Phone: 276-889-3063

Mrs. Amanda Cherie Sexton, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 2050 Pioneer Dr, Lebanon, VA 24266 Phone: 276-880-0025    Fax: 276-880-0036

Annette Leonard Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 113 Cumberland Road, Lebanon, VA 24609 Phone: 276-964-6702    Fax: 276-964-0292

Jennifer Hess Blake, LPC Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 1114 E Main St, Lebanon, VA 24266 Phone: 276-701-0030

Dr. Richard Wayne Carroll Jr., PH.D., L.P.C. Counselor - Professional Medicare: Not Enrolled in Medicare Practice Location: 320 Sword Street, Lebanon, VA 24266 Phone: 276-889-3700

Isabella Cantrell, LPC Counselor Medicare: Not Enrolled in Medicare Practice Location: 2050 Pioneer Dr, Lebanon, VA 24266 Phone: 276-880-0025    Fax: 276-880-0036

News Archive

Inhibitex completes INX-189 Phase1a trial for HCV

Inhibitex, Inc., announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 mg, or placebo. The Company plans to present detailed results from this trial during a future scientific meeting.

Quality of life assessment tools and measures not widely used in treatment of cancer patients

A new study, conducted by the not-for-profit research organisation RAND Europe, has found that measures and tools used to assess quality of life are not being used widely in the treatment and care of patients with cancer, despite being used more widely in clinical trials.

Landmark 30-year study describes clinical course of patients with Crigler-Najjar syndrome

A new study summarizes more than 30 years of clinical experience and describes the clinical course of 28 individuals homozygous for damaging mutations in the UGT1A1 gene who were born between 1984 and 2015 with Crigler-Najjar syndrome.

Younger women with SCAD may benefit most from conservative treatment

Patients who suffer from a type of heart attack that affects mainly younger women, called spontaneous coronary artery dissection or SCAD, may benefit most from conservative treatment, letting the body heal on its own.

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Warner Chilcott plc today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter.

Read more Medical News

› Verified 7 days ago